These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 2989632)

  • 1. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment.
    Yoburn BC; Goodman RR; Cohen AH; Pasternak GW; Inturrisi CE
    Life Sci; 1985 Jun; 36(24):2325-32. PubMed ID: 2989632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic supersensitivity and opioid receptor upregulation in the mouse.
    Yoburn BC; Nunes FA; Adler B; Pasternak GW; Inturrisi CE
    J Pharmacol Exp Ther; 1986 Oct; 239(1):132-5. PubMed ID: 3020228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic opioid antagonist treatment: assessment of receptor upregulation.
    Yoburn BC; Sierra V; Lutfy K
    Eur J Pharmacol; 1989 Nov; 170(3):193-200. PubMed ID: 2559854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous development of opioid tolerance and opioid antagonist-induced receptor upregulation.
    Yoburn BC; Sierra V; Lutfy K
    Brain Res; 1990 Oct; 529(1-2):143-8. PubMed ID: 2178026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE.
    Yoburn BC; Luke MC; Pasternak GW; Inturrisi CE
    Life Sci; 1988; 43(16):1319-24. PubMed ID: 2845219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors.
    Hynes MD; Lochner MA; Bemis KG; Hymson DL
    Life Sci; 1985 Jun; 36(24):2317-23. PubMed ID: 2989631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone-induced opiate receptor supersensitivity.
    Zukin RS; Sugarman JR; Fitz-Syage ML; Gardner EL; Zukin SR; Gintzler AR
    Brain Res; 1982 Aug; 245(2):285-92. PubMed ID: 6289965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat.
    Bardo MT; Bhatnagar RK; Gebhart GF
    Brain Res; 1983 Dec; 289(1-2):223-34. PubMed ID: 6318895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic opioid antagonist treatment facilitates nonopioid, stress-induced analgesia.
    Yoburn BC; Truesdell LS; Kest B; Inturrisi CE; Bodnar RJ
    Pharmacol Biochem Behav; 1987 Jul; 27(3):525-7. PubMed ID: 2821554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of beta-funaltrexamine on radiolabeled opioid binding.
    Recht LD; Pasternak GW
    Eur J Pharmacol; 1987 Aug; 140(2):209-14. PubMed ID: 2822439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of beta-FNA on opiate delta receptor binding.
    Rothman RB; Schumacher UK; Pert CB
    J Neurochem; 1984 Oct; 43(4):1197-200. PubMed ID: 6088697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists.
    Takemori AE; Portoghese PS
    Eur J Pharmacol; 1984 Sep; 104(1-2):101-4. PubMed ID: 6094203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
    Hahn EF; Nishimura S; Goodman RR; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple morphine and enkephalin receptors: biochemical and pharmacological aspects.
    Pasternak GW
    Ann N Y Acad Sci; 1986; 467():130-9. PubMed ID: 3014970
    [No Abstract]   [Full Text] [Related]  

  • 15. Apparent pA2 value of naltrexone is not changed in rats following continuous exposure to morphine or naloxone.
    Paronis CA; Holtzman SG
    Life Sci; 1992; 50(19):1407-16. PubMed ID: 1573974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
    Locke KW; Holtzman SG
    J Pharmacol Exp Ther; 1986 Sep; 238(3):990-6. PubMed ID: 3018230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds.
    Isenberg KE; Cicero TJ
    Eur J Pharmacol; 1984 Aug; 103(1-2):57-63. PubMed ID: 6090179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Stability of opiate receptors of wet and lyophilized preparations of rat brain membranes].
    Zaĭtsev SV; Kurochkin IN; Sergeeva MG; Varfolomeev SD
    Biokhimiia; 1984 Jul; 49(7):1127-33. PubMed ID: 6089917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphine-like analgesic actions of enkephalin-like peptides containing the Tyr-Arg unit.
    Takagi H; Amano H; Nakamura A; Kubota M; Nagase O; Yajima H
    Life Sci; 1982 Nov 15-22; 31(20-21):2245-8. PubMed ID: 6298521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic morphine upregulates a mu-opiate binding site labeled by [3H]cycloFOXY: a novel opiate antagonist suitable for positron emission tomography.
    Rothman RB; McLean S; Bykov V; Lessor RA; Jacobson AE; Rice KC; Holaday JW
    Eur J Pharmacol; 1987 Oct; 142(1):73-81. PubMed ID: 2826178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.